Verrica Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Verrica Pharmaceuticals Inc. (VRCA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.63 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.62M shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 8.71K shares, a 99.84% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 383.44K shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.56K shares, a 98.55% decline year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 934.67K shares, a 80.64% increase from fiscal 2024.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 517.43K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.62M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.63M shares 10-Q · filed 2026-08-06 | 2.02M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.02M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 8.71K shares 10-Q · filed 2026-05-12 | 392.15K shares derived: sum of 2 quarters · filed 2026-05-12 | 393.71K shares derived: sum of 3 quarters · filed 2026-05-12 | -4.43M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 383.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | 385.00K shares derived: sum of 2 quarters · filed 2026-03-11 | -4.44M shares derived: sum of 3 quarters · filed 2026-03-11 | 934.67K shares 10-K · filed 2026-03-11 |
| 2025-09-30 | 1.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -4.82M shares derived: sum of 2 quarters · filed 2025-11-14 | 551.23K shares 10-Q · filed 2025-11-14 | -267.64K shares derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-06-30 | -4.82M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 549.67K shares 10-Q · filed 2025-08-12 | -269.20K shares derived: sum of 3 quarters · filed 2026-03-11 | -161.60K shares derived: sum of 4 quarters · filed 2026-03-11 |
| 2025-03-31 | 5.37M shares 10-Q · filed 2025-05-13 | 4.55M shares derived: sum of 2 quarters · filed 2026-03-11 | 4.66M shares derived: sum of 3 quarters · filed 2026-03-11 | 4.81M shares derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-12-31 | -818.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -711.27K shares derived: sum of 2 quarters · filed 2026-03-11 | -561.87K shares derived: sum of 3 quarters · filed 2026-03-11 | 517.43K shares 10-K · filed 2026-03-11 |
| 2024-09-30 | 107.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 257.00K shares derived: sum of 2 quarters · filed 2024-11-05 | 1.34M shares 10-Q · filed 2024-11-05 | |
| 2024-06-30 | 149.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.23M shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 1.08M shares 10-Q · filed 2024-05-13 | |||
| 2023-09-30 | 403.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 730.84K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.58M shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 327.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.18M shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 848.00K shares 10-Q · filed 2023-05-09 | |||
| 2022-09-30 | 589.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 657.94K shares derived: sum of 2 quarters · filed 2022-11-07 | 1.02M shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 68.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 433.54K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 365.00K shares 10-Q · filed 2022-05-09 | |||
| 2021-09-30 | 157.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 385.89K shares derived: sum of 2 quarters · filed 2021-11-12 | 1.12M shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 228.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 965.74K shares 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | 736.90K shares 10-Q · filed 2021-05-07 | |||
| 2020-09-30 | 381.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 425.50K shares derived: sum of 2 quarters · filed 2020-11-09 | 1.09M shares 10-Q · filed 2020-11-09 | |
| 2020-06-30 | 44.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | 705.20K shares 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | 660.70K shares 10-Q · filed 2020-05-07 | |||
| 2019-06-30 | 607.58K shares 10-Q · filed 2019-08-07 | |||
| 2017-06-30 | 0.00 shares 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |